Coluracetam (MKC-231) is a synthetic Racetam drug purported to be a Nootropic compound. It does not have a large body of evidence investigating it, but the mechanisms of action (as well as structute) appear to be very distinct from other racetam compounds like Piracetam or Aniracetam.
Coluracetam appears to interact with a process known as high affinity choline uptake (HACU for short), which is the rate-limiting step of drawing choline into a neuron for synthesis into the neurotransmitter acetylcholine. Increasing the HACU rate appears to increase the activity of cholinergic neurons, so it is a desired target for cognitive enhancement.
Interventions in rats (as there is no human evidence currently) support the usage of coluracetam at very low oral doses to preserve HACU that is otherwise impaired by the use of research drugs that are known to impair HACU. The limited evidence looking at the inherent effects of coluracetam on the HACU of normal neurons has failed to find any significant interaction.
Coluracetam has also been noted to associate with choline transporters physically, but it is not known exactly what it does once associated.
Overall, there is currently insufficient evidence to support the usage of coluracetam for cognitive enhancement. Further studies are needed to see if it has a therapeutic role in instances where HACU may be impaired (such as Alzheimer's disease).
Follow this Page for updates
The animal research on coluracetam uses an oral dose of 300-3,000mcg/kg bodyweight, which is roughly translated into a human dose of 48-480mcg/kg or (for a 150lb person) 3.2-32.7mg overall.
It appears to have very rapid kinetics, with a peak in blood at around 30 minutes and on the decline within 3 hours. Due to this, supplementation may be time-dependent in relation to activity.
Coluracetam (full structural name of 2-(2-oxopyrrolidin-1-yl)-N-(2,3-dimethyl-5,6,7,8-tetrahydrofuro2,3-b quinolin-4-yl)acetoamide and codenames of MKC-231 or BCI-540) is a Racetam compound formulated as a Nootropic for the purpose of cognitive enhancement.
Coluracetam is a synthetic drug of the racetam family designed to support cholinergic function, particular for the treatment of Alzheimer's
A known metabolite is hydroxylated coluracetam on the 2-carbon of the pyrrolidinone backbone, it is sometimes referred to as M-MKC-231. It appears inactive on the main mechanism of action coluracetam is known for (increasing HACU).
Coluracetam is a highly modified pyrrolidinone backbone
Plasma concentrations of coluracetam in rats following oral ingestion of 10mg/kg have been noted to be 4.289+/-0.641µg/mL (30 minutes), 0.717+/-0.350µg/mL (3 hours), and 0.037+/-0.010µg/mL (24 hours). The kinetics following seven or fourteen days of supplementation was similar.
Coluracetam has been detected in plasma following oral ingestion, and appears to be able to reach high levels within 30 minutes and is already on the decline within 3 hours
Oral intake of 10mg/kg coluracetam to rats has been noted to be detected in the brain at 30 minutes post-ingestion (210+/-54ng/g wet weight) and is detectable at three hours (30+/-16ng/g wet weight) but not a day after ingestion. Supplementation of coluracetam for 7-14 days does not alter these kinetics.
Coluracetam can be detected in neural tissue within 30 minutes of ingestion, and is significantly reduced in concentration within 3 hours
High affinity choline uptake (HACU) is the uptake of choline at the synpase for the purpose of acetylcholine synthesis, and is seen as a rate-limiting step of acetylcholine synthesis. Coluracetam appears to associated with these transporters.
HACU appears to be a rate-limiting step of acetylcholine synthesis
Coluracetam has been noted to, in rats treated with choline uptake inhibitors (such as AF64A), increase choline uptake and acetylcholine synthesis associated with an increase in Vmax (1.7-fold) and Bmax (1.6-fold) at 10nM concentration. KM appears unaffected from coluracetam, but is not inherently impaired by the research toxin AF64A.
HACU does not appear to be influence in hippocampal slices derived from rats not treated with choline uptake inhibitors, with both the KM and Vmax being unaffected as well. Additionally, ligand (HC-3) binding to cholinergic receptors in normal rats appears unaffected.
Coluracetam appears to be able to increase the activity of this step when it is otherwise impaired but preliminary evidence suggests that this is not an inherent effect
Hippocampal concentrations of acetylcholine that are reduced by HACU inhibitors are able to be partially preserved with oral treatment of 300-1,000mcg/kg coluracetam over twelve days with no acute effect nor benefit with 3mg/kg.
Coluracetam may be able to attenuate learning deficits seen with choline uptake inhibitors as assessed by water maze, and is active orally at the dosage of 1-10mg/kg in rats. Elsewhere, the effects of 300-3,000mcg coluracetam have not been detected after single administration but were present (near full restoration of performance in a T-maze) after 12 days. Benefits to cognition in this research model (AF64A treated) have been noted at 1-3mg/kg coluracetam to extend for up to two days after supplement cessation despite no detectable coluracetam in the brain (no significant benefit on the third day).
One study has noted that the cholinergic dysfunction induced in rats by phencyclidine (a research drug to induce symptoms associated with schizophrenia) also given 3mg/kg coluracetam twice daily resulted in significantly less cognitive disturbance (assessed by object recognition) although it was without effect on passive avoidance learning nor locomotor changes.
Coluracetam appears to preserve and/or normalize cholinergic dysfunction in the presence of underactive of chemically impaired HACU, but there is no research to support an inherent cognitive boosting effect
In cultured corticol neurons, coluracetam is able to reduce the excitotoxicity caused by either glutamate or calcium influx but is ineffective against nitric oxide donors. Practical significance of this data is uncertain as the tests were conducted at 10µM, a higher than normal concentration for this molecule.
Suggests protective effects, but this information may not be relevant due to the high concentration used
(Common misspellings for Coluracetam include colracetam, koluracetam, coliracetam, coleracetam)
(Common phrases used by users for this page include coluraxetam, coluracetam, dosage, coluracetam mechanism, coluracetam high, coluracetam examine, coluracetam dosage)
(Users who contributed to this page include KurtisFrank)